IDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been given an average rating of “Hold” by the nine analysts that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $187.33.

Several analysts have issued reports on IDXX shares. Canaccord Genuity restated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research note on Friday, October 6th. Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Finally, BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th.

Shares of IDEXX Laboratories (NASDAQ IDXX) traded up $3.57 during trading on Tuesday, reaching $176.81. The company had a trading volume of 242,755 shares, compared to its average volume of 482,989. The company has a market capitalization of $15,370.00, a price-to-earnings ratio of 57.41, a P/E/G ratio of 2.34 and a beta of 0.42. IDEXX Laboratories has a 1-year low of $116.54 and a 1-year high of $173.82. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. IDEXX Laboratories’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the company posted $0.62 earnings per share. research analysts anticipate that IDEXX Laboratories will post 3.24 EPS for the current fiscal year.

In other news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $153.75, for a total value of $2,767,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $163,678,098.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Giovani Twigge sold 2,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 130,160 shares of company stock valued at $20,019,685. 2.77% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in IDXX. D.A. Davidson & CO. grew its position in shares of IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after purchasing an additional 385 shares in the last quarter. Sun Life Financial INC grew its position in shares of IDEXX Laboratories by 9,085.7% in the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after purchasing an additional 636 shares in the last quarter. BB&T Investment Services Inc. purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $104,000. Zions Bancorporation purchased a new position in shares of IDEXX Laboratories in the third quarter valued at $162,000. Finally, BB&T Securities LLC purchased a new position in shares of IDEXX Laboratories in the third quarter valued at $213,000. Institutional investors own 86.66% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/16/idexx-laboratories-inc-idxx-given-consensus-recommendation-of-hold-by-brokerages.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply